Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients

NCT03823352 | Completed Phase 2

• 1 other identifier: GHAML-2-001
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 2

Brief Summary

This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule, 100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.

Conditions

Leukemia, Myeloid, Acute

Outcome Measures

Primary Outcomes (1)

• Complete blood count measurements according International Working Group (IWG) response criteria

  Evaluation of preliminary efficacy profile of antroquinonol in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible.

  2 weeks

Secondary Outcomes (2)

• Number of Participants alive at 4weeks

  4 weeks

• Number of Participants alive at 24 weeks

  24 weeks

Study Arms (1)

Antroquinonol

EXPERIMENTAL

Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.

Drug: Antroquinonol

Interventions

Antroquinonol DRUG

Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.

Also known as: Hocena

Antroquinonol

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of relapsed AML after at least 1 chemotherapy regimen or at initial diagnosis when no intensive treatment possible (based on standard criteria).
• Men and women 18 to 70 years of age.
• ECOG performance status = 0 or 1.
• Ability to comply with the study requirements and give written informed consent.
• Expected survival more than 3 months.
• Patients with preserved reproductive potential agree to use, with their partner, adequate contraception throughout the study and for 30 days thereafter (contraceptive methods with reliability greater than 90%: cervical caps with spermicide, diaphragms with spermicide, condoms with intravaginal spermicide, non-hormonal intrauterine devices), or true sexual abstinence.

You may not qualify if:

• Acute promyelocytic leukemia (APL).
• Hemoglobin ≤ 7g/dL or platelet ≤ 50,000.
• Abnormal liver and renal function:
• Total bilirubin \> 2 mg/dL;
• AST and ALT \> 2.5 × ULN;
• Creatinine \> 1.5 × ULN, OR creatinine clearance \< 50 mL/min/1.73m2.
• The subject has not recovered to grade ≤ 1 adverse events due to investigational or chemotherapeutic drugs or stem cell transplantation which were administered \> 4 weeks prior to study enrollment.
• Patient who has had in the past 3 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ ductal carcinoma of the breast.
• Subjects with any serious active infection (i.e., requiring an intravenous antibiotic, antifungal, or antiviral agent).
• Subjects with known human immunodeficiency virus, active hepatitis B or C.
• Subjects who have any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise subject safety or interfere with the evaluation of the safety of the study drug.
• Known or suspected substance abuse or alcohol abuse.
• Patients with history of seizure disorders or central nervous system leukemia.
• Patients with uncontrolled, intercurrent illness including, but not limited to, symptomatic neurological illness; active, uncontrolled, systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; significant pulmonary disease or hypoxia; or psychiatric illness/social situations that would limit compliance with study requirements.
• Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea e.g., Crohn's disease, malabsorption, or CTCAE Grade \> 2 diarrhea of any etiology at baseline.

Sponsors & Collaborators

• Golden Biotechnology Corporation: lead

Study Sites (2)

City Clinical Hospital n.a. S.P.Botkin

Moscow, 125101, Russia

Location

Tula Regional Clinical Hospital

Tula, 300053, Russia

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

antroquinonol

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.

Study Record Dates

• First Submitted: January 27, 2019
• First Posted: January 30, 2019
• Study Start: February 20, 2019
• Primary Completion: December 31, 2020
• Study Completion: December 31, 2020
• Last Updated: February 3, 2021

Record last verified: 2021-02

Data Sharing

• IPD Sharing: Will not share

Locations

RU (2)